

CONTENTS

NOTE TO THE READER	1
LIST OF PARTICIPANTS	3
PREAMBLE	9
A. General Principles and Procedures.....	9
1. Background.....	9
2. Objective and scope.....	10
3. Selection of agents for review.....	11
4. Data for the <i>Monographs</i>	12
5. Meeting participants.....	12
6. Working procedures.....	13
B. Scientific Review and Evaluation.....	14
1. Exposure data.....	15
2. Studies of cancer in humans.....	16
3. Studies of cancer in experimental animals.....	20
4. Mechanistic and other relevant data.....	23
5. Summary.....	26
6. Evaluation and rationale.....	27
References.....	31
GENERAL REMARKS	33
WELDING	36
1. Exposure Data.....	37
1.1 Description of major welding processes and materials.....	37
1.2 Measurement and analysis.....	50

1.3 Occurrence and exposure.....	52
1.4 Regulations and guidelines.....	67
1.5 Exposure assessment of epidemiological studies.....	68
References.....	82
2. Cancer in Humans.....	89
2.1 Introduction.....	89
2.2 Ocular melanoma.....	90
2.3 Mesothelioma.....	112
2.4 Cohort studies.....	113
2.5 Case-control studies.....	157
2.6 Occupational studies of cancer mortality and incidence based on routinely collected data....	197
References.....	199
3. Cancer in Experimental Animals.....	211
3.1 Mouse.....	211
3.2 Rat.....	219
3.3 Hamster.....	219
References.....	220
4. Mechanistic and Other Relevant Data.....	221
4.1 Absorption, distribution, and excretion.....	221
4.2 Mechanisms of carcinogenesis.....	225
4.3 Cancer susceptibility.....	244
4.4 Other adverse effects.....	244
References.....	246
5. Summary of Data Reported.....	255
5.1 Exposure data.....	255
5.2 Human carcinogenicity data.....	256
5.3 Animal carcinogenicity data.....	261
5.4 Mechanistic and other relevant data.....	262
6. Evaluation.....	265
6.1 Cancer in humans.....	265
6.2 Cancer in experimental animals.....	265
6.3 Overall evaluation.....	265
MOLYBDENUM TRIOXIDE.....	267
1. Exposure Data.....	267
1.1 Identification.....	267
1.2 Production and use.....	267
1.3 Measurement and analysis.....	268
1.4 Occurrence and exposure.....	269
1.5 Regulations and guidelines.....	272

2. Cancer in Humans	272
3. Cancer in Experimental Animals	272
3.1 Mouse	272
3.2 Rat	275
4. Mechanistic and Other Relevant Data	276
4.1 Toxicokinetic data	276
4.2 Mechanisms of carcinogenesis	276
4.3 Cancer susceptibility	277
4.4 Other adverse effects	277
5. Summary of Data Reported	277
5.1 Exposure data	277
5.2 Human carcinogenicity data	278
5.3 Animal carcinogenicity data	278
5.4 Mechanistic and other relevant data	278
6. Evaluation	278
6.1 Cancer in humans	278
6.2 Cancer in experimental animals	279
6.3 Overall evaluation	279
References	279
INDIUM TIN OXIDE	283
1. Exposure Data	283
1.1 Identification	283
1.2 Production and use	283
1.3 Measurement and analysis	284
1.4 Occurrence and exposure	285
1.5 Regulations and guidelines	290
2. Cancer in Humans	290
3. Cancer in Experimental Animals	290
3.1 Mouse	291
3.2 Rat	291
3.3 Hamster	295
4. Mechanistic and Other Relevant Data	296
4.1 Toxicokinetic data	296
4.2 Mechanisms of carcinogenesis	298
4.3 Cancer susceptibility	301
4.4 Other adverse effects	301

5. Summary of Data Reported	302
5.1 Exposure data.....	302
5.2 Human carcinogenicity data	302
5.3 Animal carcinogenicity data.....	302
5.4 Mechanistic and other relevant data.....	303
6. Evaluation.....	304
6.1 Cancer in humans.....	304
6.2 Cancer in experimental animals	304
6.3 Overall evaluation	304
References.....	304
LIST OF ABBREVIATIONS	307

NOTE TO THE READER

The term ‘carcinogenic risk’ in the *IARC Monographs* series is taken to mean that an agent is capable of causing cancer. The *Monographs* evaluate cancer hazards, despite the historical presence of the word ‘risks’ in the title.

Inclusion of an agent in the *Monographs* does not imply that it is a carcinogen, only that the published data have been examined. Equally, the fact that an agent has not yet been evaluated in a *Monograph* does not mean that it is not carcinogenic. Similarly, identification of cancer sites with *sufficient evidence* or *limited evidence* in humans should not be viewed as precluding the possibility that an agent may cause cancer at other sites.

The evaluations of carcinogenic risk are made by international working groups of independent scientists and are qualitative in nature. No recommendation is given for regulation or legislation.

Anyone who is aware of published data that may alter the evaluation of the carcinogenic risk of an agent to humans is encouraged to make this information available to the Section of IARC Monographs, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France, in order that the agent may be considered for re-evaluation by a future Working Group.

Although every effort is made to prepare the *Monographs* as accurately as possible, mistakes may occur. Readers are requested to communicate any errors to the Section of IARC Monographs, so that corrections can be reported in future volumes.